Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma. / Kisaretova, Polina E.; Kirikovich, Svetlana S.; Ritter, Genrich S. и др.
в: Anticancer research, Том 40, № 2, 01.02.2020, стр. 795-805.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma
AU - Kisaretova, Polina E.
AU - Kirikovich, Svetlana S.
AU - Ritter, Genrich S.
AU - Efremov, Yaroslav R.
AU - Taranov, Oleg S.
AU - Dubatolova, Tatyana D.
AU - Proskurina, Anastasia S.
AU - Potter, Ekaterina A.
AU - Dolgova, Evgenia V.
AU - Sidorov, Sergey V.
AU - Ostanin, Aleksandr A.
AU - Chernych, Elena R.
AU - Bogachev, Sergey S.
N1 - Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - BACKGROUND/AIM: We previously have described the "3+1" tumors cure approach consisting of individual time schedule of cyclophosphamide and dsDNA preparation administrations. The aim of the study was to adapt the "3+1" approach based on eradication of cancer stem cells to the model of murine ascitic cyclophosphamide-resistant lymphosarcoma (RLS). MATERIALS AND METHODS: Adaptation of the "3+1" approach includes the identification of the timing to disrupt the tumorigenic potential of a certain tumor. RESULTS: The proposed therapeutic scheme allowed complete reduction of primary RLS ascites in experimental animals. However, reduction of primary ascites due to the complementary action of cyclophosphamide and dsDNA was inevitably followed by the development of a secondary one, most likely arising from a solid carcinomatous formation in the peritoneal wall. CONCLUSION: The "3+1" approach resulted in the elimination of cancer stem cells, and, as a consequence, in the complete reduction of RLS ascites.
AB - BACKGROUND/AIM: We previously have described the "3+1" tumors cure approach consisting of individual time schedule of cyclophosphamide and dsDNA preparation administrations. The aim of the study was to adapt the "3+1" approach based on eradication of cancer stem cells to the model of murine ascitic cyclophosphamide-resistant lymphosarcoma (RLS). MATERIALS AND METHODS: Adaptation of the "3+1" approach includes the identification of the timing to disrupt the tumorigenic potential of a certain tumor. RESULTS: The proposed therapeutic scheme allowed complete reduction of primary RLS ascites in experimental animals. However, reduction of primary ascites due to the complementary action of cyclophosphamide and dsDNA was inevitably followed by the development of a secondary one, most likely arising from a solid carcinomatous formation in the peritoneal wall. CONCLUSION: The "3+1" approach resulted in the elimination of cancer stem cells, and, as a consequence, in the complete reduction of RLS ascites.
KW - cancer stem cells eradication
KW - cyclophosphamide
KW - double-stranded DNA
KW - RLS lymphosarcoma
KW - secondary ascites
KW - Cyclophosphamide
KW - Doublestranded DNA
KW - Secondary ascites
KW - Cancer stem cells eradication
UR - http://www.scopus.com/inward/record.url?scp=85078929012&partnerID=8YFLogxK
U2 - 10.21873/anticanres.14011
DO - 10.21873/anticanres.14011
M3 - Article
C2 - 32014922
AN - SCOPUS:85078929012
VL - 40
SP - 795
EP - 805
JO - Anticancer research
JF - Anticancer research
SN - 0250-7005
IS - 2
ER -
ID: 23427444